OPKO HEALTH INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
OPK$1.71-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash, cash equivalents and current restricted cash | $431,936 | $95,881 |
| Accounts receivable, net | 118,017 | 123,379 |
| Inventory, net | 56,797 | 65,697 |
| Other current assets and prepaid expenses | 55,339 | 24,519 |
| Total current assets | 662,089 | 309,476 |
| Property, plant and equipment, net | 70,134 | 75,429 |
| Intangible assets, net | 616,613 | 740,283 |
| In-process research and development | 195,000 | 195,000 |
| Goodwill | 529,252 | 598,260 |
| Investments | 54,584 | 16,082 |
| Operating lease right-of-use assets | 54,003 | 68,088 |
| Other assets | 18,537 | 9,080 |
| Total assets | $2,200,212 | $2,011,698 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $47,071 | $69,677 |
| Accrued expenses | 118,357 | 90,086 |
| Current maturities of operating leases | 12,649 | 12,996 |
| Current portion of convertible notes | 170 | — |
| Current portion of lines of credit and notes payable | 14,849 | 27,293 |
| Total current liabilities | 193,096 | 200,052 |
| Operating lease liabilities | 48,849 | 54,140 |
| Long term portion of convertible notes | 173,606 | 214,325 |
| Senior secured notes | 245,576 | — |
| Deferred tax liabilities | 140,799 | 126,773 |
| Other long-term liabilities, principally contingent consideration and lines of credit | 32,838 | 27,189 |
| Total long-term liabilities | 641,668 | 422,427 |
| Total liabilities | 834,764 | 622,479 |
| Equity: | ||
| Common Stock - $0.01 par value, 1,250,000,000 shares authorized; 701,350,447 and 781,936,885 shares issued at December 31, 2024 and 2023, respectively | 7,015 | 7,820 |
| Treasury Stock, - 29,799,907 shares at December 31, 2024 and 2023, respectively | (1,791) | (1,791) |
| Additional paid-in capital | 3,481,364 | 3,433,006 |
| Accumulated other comprehensive loss | (56,130) | (38,030) |
| Accumulated deficit | (2,065,010) | (2,011,786) |
| Total shareholders’ equity | 1,365,448 | 1,389,219 |
| Total liabilities and equity | $2,200,212 | $2,011,698 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.